Davis Hugh M. 4

What Happened Hugh M. Davis, President, Chief Operating Officer and a director of Aclaris Therapeutics (ACRS), had 18,675 restricted stock units (RSUs) convert into 18,675 shares on February 3, 2026. The filing shows an acquisition via conversion/exercise of a derivative (18,675 shares) and a simultaneous disposition of 18,675 shares at $0.00. No cash purchase or open-market sale is reported; this is a vesting/conversion event, not a typical buy or sell for investment purposes. The filing was submitted on February 5, 2026.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (timely).
• Acquired: 18,675 shares via conversion/exercise of derivative (RSUs). Disposed: 18,675 shares at $0.00 (derivative).
• Reported prices/values: acquisition price shown as N/A; disposition recorded at $0.00 — no cash proceeds reported.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes from the filing:
  • F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
  • F2: The underlying RSUs vest in four equal installments on the 1st–4th anniversaries of February 3, 2025, subject to continuous service.
• No 10b5-1 plan, tax-withholding footnote, or late-filing indicator is explicitly reported in the provided data.

Context This appears to be the first vesting installment (one-quarter) of an RSU grant dated February 3, 2025 — a routine equity compensation vesting event rather than a directional purchase or sale. The simultaneous disposition at $0.00 commonly reflects shares withheld or net-settled under the company plan to satisfy tax or other withholding obligations, though the filing does not explicitly state the reason. For retail investors, conversions/vestings are generally neutral signals about insider sentiment compared with open-market purchases or sales.